Role of Glucagon-like Peptide-1 (GLP-1) receptor agonists versus DPP-4 inhibitors for alcohol and substance use disorders in improving HIV-related outcomes and providing health benefits in people living with HIV

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

NATIONAL INSTITUTES OF HEALTH NIDA

Contract Value

Not provided

Codes & Classification
Solicitation Number

75N95026R0007

NAICS

541690 - Other Scientific and Technical Consulting Services

Classification Code

B529

Additional Details
Set Aside

NONE

Place of Performance

Bethesda, Maryland, UNITED STATES

SourceSAM
Documents3
The National Institutes of Health (NIH), specifically the National Institute on Drug Abuse (NIDA), has issued a combined synopsis/solicitation (Solicitation Number: 75N95026R0007) for a research-focused procurement titled "Role of Glucagon-like Peptide-1 (GLP-1) receptor agonists versus DPP-4 inhibitors for alcohol and substance use disorders in improving HIV-related outcomes and providing health benefits in people living with HIV." This opportunity is classified under NAICS code 541690 (Other Scientific and Technical Consulting Services), with a small business size standard of $19.0 million, and is being competed on a full and open basis with no set-aside restrictions. **Purpose and Scope:** The primary objective of this procurement is to conduct a comprehensive analysis of the potential health benefits of GLP-1 receptor agonists (GLP-1RAs) compared to DPP-4 inhibitors in people living with HIV (PLWH), particularly in the context of alcohol and substance use disorders (ASUD). The project will leverage electronic health record data from the Department of Veterans Affairs (VA), the largest integrated healthcare system in the United States, to investigate associations between GLP-1RA exposure (for any indication) and outcomes related to HIV and ASUD in adult populations. The study design includes propensity-score matching of individuals exposed to GLP-1RAs with up to five unexposed individuals, followed by multivariable linear regression analyses to estimate changes in relevant health outcomes before and after exposure. **Key Requirements and Deliverables:** Offerors are expected to provide services in accordance with the attached Statement of Work (SOW), which details the specific requirements and deliverables. While the SOW is referenced for full details, the solicitation emphasizes the need for technical expertise in data analysis, epidemiology, and clinical research related to HIV, substance use disorders, and pharmacological interventions. Deliverables will likely include comprehensive data analyses, interim and final reports, and possibly recommendations for future research or clinical practice, as inferred from the project scope. **Contract Structure and Period of Performance:** The Government anticipates awarding a firm fixed-price purchase order for this requirement. The base period of performance is projected from August 7, 2026, through August 6, 2027, with three additional twelve-month option periods, allowing for a potential total contract duration of up to four years. **Evaluation Criteria:** Proposals will be evaluated based on technical capability, price, and past performance, with technical factors being significantly more important than price. Offerors must demonstrate clear and convincing evidence of their ability to fulfill the technical requirements, including relevant experience, methodologies, and resources. Price proposals should include detailed labor categories, estimated hours, fully loaded rates, and a rationale for any other direct costs or materials. **Contracting Entity and Location:** The contracting entity is the National Institutes of Health, NIDA, located in Bethesda, Maryland. The place of performance is also Bethesda, MD. The primary point of contact for this solicitation is Robin Knightly, Contracting Officer, who can be reached at [email protected] or 301-827-5302. **Regulatory and Compliance Considerations:** This solicitation incorporates a comprehensive set of Federal Acquisition Regulation (FAR) clauses and provisions, including those related to labor standards, equal opportunity, small business utilization, and security requirements. Notably, the Service Contract Labor Standards statute applies, with special provisions for unknown places of performance. Offerors must be actively registered in the System for Award Management (SAM) and provide their Unique Entity Identifier (UEI), Taxpayer Identification Number (TIN), and business size certification with their response. **Submission Instructions and Timeline:** Responses must be submitted electronically to Robin Knightly by 9:00 a.m. EST on July 30, 2026, referencing solicitation number 75N95026R0007. All proposals should adhere to the instructions outlined in the solicitation, including the inclusion of all required representations and certifications. **Summary for Contractors:** This opportunity is well-suited for organizations with demonstrated expertise in scientific and technical consulting, particularly those with experience in large-scale health data analysis, HIV research, and the evaluation of pharmacological interventions for substance use disorders. The project’s reliance on VA electronic health records and advanced statistical methodologies requires a high level of technical proficiency and familiarity with healthcare data systems. Contractors should ensure their proposals clearly address the technical evaluation criteria and provide robust evidence of past performance in similar research domains. For further details, including the full Statement of Work and applicable clauses, interested parties should review the solicitation documents available at the provided SAM.gov link: https://sam.gov/opp/39c13aa6756e4ac2bc3ab83cc43acf71/view.